Rifaximin provides significant relief of irritable bowel syndrome symptoms

January 5, 2011, University of North Carolina School of Medicine
Yehuda Ringel, M.D., of the University of North Carolina at Chapel Hill, is a co-author of these two studies. Credit: UNC Medical Center News Office

A pair of clinical trials, conducted in part at the University of North Carolina at Chapel Hill, found that two weeks of treatment with rifaximin provides significant relief of irritable bowel syndrome symptoms including bloating, abdominal pain and loose or watery stools.

In addition, the studies found that the benefits of treatment with (brand name: Xifaxan) persisted for 10 weeks after patients stopped taking the broad-spectrum antibiotic, said Yehuda Ringel, MD, an associate professor of medicine in the UNC School of Medicine and a co-author of the studies, which are published in the Jan. 6, 2011 issue of the .

"These results support the idea that intestinal microbiota or may be an underlying cause of IBS, and altering gut bacteria by treatment with rifaximin appears to be an effective way of providing relief to those who suffer from IBS symptoms," Dr. Ringel said.

First author of the studies is Mark Pimentel, MD of Cedars-Sinai Medical Center in Los Angeles. The corresponding author is William P. Forbes, PharmD, of Salix Pharmaceuticals of Morrisville, N.C., which makes the drug and funded the studies.

The two studies, known as TARGET 1 and TARGET 2, were conducted in parallel from June 2008 through June 2009. In the studies, a total of 1,260 patients who had (IBS) without constipation were enrolled at one of 179 study sites in the U.S. and Canada. All were randomized to receive the study drug in 550 milligram doses, three times daily for two weeks, or placebo. All were then followed for an additional 10 weeks.

During the first four weeks after treatment, 40.7 percent of the patients in the rifaximin group reported adequate relief of global IBS symptoms, compared to 31.7 percent in the placebo group. Similarly, 40.2 percent in the rifaximin group had adequate relief of bloating, compared to 30.3 percent on placebo. Also, significantly more patients taking the study drug reported adequate reductions of abdominal pain and loose or watery stools.

The studies concluded that taking 550 milligram doses of rifaximin three times a day for 14 days provides better relief of IBS symptoms than placebo for up to 10 weeks after completion of therapy.

Dr. Ringel added that rifaximin, which is a semisynthetic antibiotic, has additional advantages including low systemic absorption (more than 99 percent is secreted in the stool), good antibacterial activity, low microbial resistance and a high safety profile.

"These studies support the idea that gut bacteria have an important role in maintaining normal intestinal function and emphasize the need for further research on the interaction between the intestinal microbiota and the human host," Dr. Ringel said.

Additional studies currently under way at UNC are aimed at providing a better understanding of the mechanisms by which changes in the composition of the intestinal microbiota can alter intestinal function and lead to gastrointestinal symptoms, Dr. Ringel said.

Related Stories

Recommended for you

Onions could hold key to fighting antibiotic resistance

January 22, 2018
A type of onion could help the fight against antibiotic resistance in cases of tuberculosis, a UCL and Birkbeck-led study suggests.

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

4 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

SincerelyTwo
not rated yet Jan 05, 2011
32% from placebo, and 41% from non-placebo. I have a feeling the only way this thing works is as a placebo effect.

Assume rifaximin doesn't work, then I would expect the non-placebo group to have very similar results to the placebo group. Which seems to be the case. If it did work I would expect the non-placebo group to be at least greater than 60%. They should try and identify why it didn't work for the majority of the non-placebo group before announcing this stuff.
Quantum_Conundrum
5 / 5 (1) Jan 05, 2011
SincerelyTwo:

Didn't you see that other recent article on placebos and irritable bowel syndrome?

In the case of irritable bowel syndrome, placebos work even when the subject knows it's a placebo.

It's possible this condition is at least partly psychological, i.e. anxiety or stress related, which explains why merely "reassuring" a patient by giving them a placebo has such a drastic effect.
Ratfish
3 / 5 (2) Jan 06, 2011
Abstaining from grain is far more effective.
jsland
5 / 5 (1) Jan 06, 2011
Everything you ingest influences your gut and your gut also sends messages directly to the brain, chemically speaking. Why does the medical "industry" insist on bypassing this truth? Money. Utilitarian solutions that bypass the wholeness of the creature so that a pill becomes a solution rather than self knowledge, the exercise of will and taking responsibility inside one's body.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.